Price (delayed)
$9.79
Market cap
$1.57B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.69
Enterprise value
$1.11B
Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III
There are no recent dividends present for NVAX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.